Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 9/20 | 0.54 |
| ▸ | BCHE | P06276 | 6/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5933261 | 0.85 | ACHE (0.71) | ACHEBCHEKDM4EALDH1A1LMNA | |
| SCHEMBL29358693 | 0.85 | ACHE (0.71) | ACHEBCHEKDM4EALDH1A1LMNA | |
| SCHEMBL18138876 | 0.85 | ACHE (0.75) | ACHEBCHEFAAH | |
| SCHEMBL10290193 | 0.83 | PTGS1 (0.51) | ACHEBCHEKDM4EALDH1A1LMNA | |
| SCHEMBL1261641 | 0.83 | LMNA (0.59) | ACHEBCHEKDM4EALDH1A1LMNA | |
| SCHEMBL28119215 | 0.81 | ACHE (0.51) | ACHEBCHEKDM4EALDH1A1LMNA | |
| SCHEMBL25847360 | 0.81 | BCHE (0.51) | ACHEBCHEALDH1A1SMN1; SMN2FAAH | |
| SCHEMBL11418025 | 0.81 | ACHE (0.53) | ACHEBCHEKDM4EALDH1A1LMNA | |
| SCHEMBL13723761 | 0.81 | ACHE (0.46) | ACHEBCHEALDH1A1 | |
| SCHEMBL28537560 | 0.81 | KMT2A (0.59) | ACHEBCHEKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | ACHE 4354/4885BCHE 3202/4885KDM4E 4219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.